TheraPten Biosciences Enters Exclusive Licensing Agreement With Columbia University to Develop Novel, Naturally-Occurring Anti-Cancer Therapeutic Protein
TheraPten Biosciences Inc., a Canadian biotechnology company, has entered into an exclusive licensing agreement with Columbia University on two globally issued patent families covering PTEN-L, a naturally-occurring tumor suppressor protein.
- Published in Diaspora